Pulmonary Hypertension :
Pathophysiology and Novel Therapies

Director : Professor Marc HUMBERT

Hopital Bicêtre

Hopital Bicêtre

Hôpital Marie Lannelongue

Faculté de Médecine Paris-Saclay Service de Pneumologie et Réanimation Respiratoire Groupe Hospitalier Paris Saint Joseph
Bâtiment de recherche (Porte 16)
Centre National de Référence de l'Hypertension Pulmonaire Département de recherche médicale
63 rue Gabriel Péri 78 Rue du Général Leclerc
133, Avenue de la Résistance
94276 Le Kremlin-Bicêtre, France 94276 Le Kremlin-Bicêtre, France
92350 Le Plessis-Robinson, France


Pulmonary hypertension describes a group of devastating diseases, comprising idiopathic and associated forms, causing breathlessness, loss of exercise capacity and death due to elevated pulmonary artery pressure and subsequent right heart failure. Pulmonary arterial hypertension is defined by a chronic elevation in mean pulmonary arterial pressure (mPAP) > 20mmHg at rest, with a normal pulmonary artery wedge pressure (≤ 15 mmHg) and increased PVR > 2 Wood Units. Extensive pulmonary artery remodeling with loss of vessel patency is the underlying pathomechanism. The main scope of the Research Team "PULMONARY HYPERTENSION: PATHOPHYSIOLOGY AND NOVEL THERAPIES" relates to pulmonary hypertension pathophysiology and clinical management. Deciphering of the mechanisms of lung vascular remodeling and identification of novel molecular targets to alleviate and ultimately cure pulmonary hypertension is the main objective of this proposal. On the basis of a nationwide web-based Registry, a biobank, and highly competitive scientists, our group will study a number of molecular pathways causing pulmonary vascular remodeling in human and animal models of pulmonary hypertension, identify targets for therapy, foster drug development based on these targets and test novel treatments. Our main goal is to alleviate and cure pulmonary hypertension, a large burden to mankind, and to develop novel therapies.